Pyrimidine biosynthesis has been previously identified as a metabolic vulnerability in PTEN-deficient glioblastoma (24), and pyrimidine biosynthesis inhibitors have been shown to potentiate the therapeutic response to PI3K inhibitors in glioblastoma (25). The gene discussed is PTEN; the disease is glioblastoma.